Literature DB >> 22192884

Nonprofit drugs as the salvation of the world's healthcare systems: the case of Antabuse (disulfiram).

Boris Cvek1.   

Abstract

The effort to repurpose old drugs for new uses is not sufficient; even drugs that have been used clinically for decades must undergo expensive clinical trials. This process requires the pharmaceutical industry to fund the repatenting of old drugs. Because inexpensive drugs are necessary for people around the world, attempts should be made to develop nonprofit drugs through clinical trials of generic drugs that are funded by governments and charities. Evidence supports the use the old anti-alcoholic drug Antabuse as a new nonprofit drug for cancer.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22192884     DOI: 10.1016/j.drudis.2011.12.010

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  33 in total

1.  Disulfiram and Copper Ions Kill Mycobacterium tuberculosis in a Synergistic Manner.

Authors:  Alex G Dalecki; Mehri Haeili; Santosh Shah; Alexander Speer; Michael Niederweis; Olaf Kutsch; Frank Wolschendorf
Journal:  Antimicrob Agents Chemother       Date:  2015-06-01       Impact factor: 5.191

2.  Diethyldithiocarbamate, an anti-abuse drug, alleviates steatohepatitis and fibrosis in rodents through modulating lipid metabolism and oxidative stress.

Authors:  Tianhui Liu; Ping Wang; Min Cong; Xinyan Zhao; Dong Zhang; Hufeng Xu; Lin Liu; Jidong Jia; Hong You
Journal:  Br J Pharmacol       Date:  2018-10-23       Impact factor: 8.739

3.  Drug Repurposing for Terminal-Stage Cancer Patients.

Authors:  Boris Cvek
Journal:  Am J Public Health       Date:  2016-06       Impact factor: 9.308

4.  Repurposing disulfiram for cancer therapy via targeted nanotechnology through enhanced tumor mass penetration and disassembly.

Authors:  Huacheng He; Eleni Markoutsa; Jing Li; Peisheng Xu
Journal:  Acta Biomater       Date:  2017-12-30       Impact factor: 8.947

Review 5.  Disulfiram: a novel repurposed drug for cancer therapy.

Authors:  Chen Lu; Xinyan Li; Yongya Ren; Xiao Zhang
Journal:  Cancer Chemother Pharmacol       Date:  2021-01-10       Impact factor: 3.333

6.  Disulfiram's journey from rubber vulcanization to T-cell activation.

Authors:  Magalie Dosset; Maurizio Zanetti
Journal:  EMBO J       Date:  2022-07-18       Impact factor: 14.012

Review 7.  Recent advances in the delivery of disulfiram: a critical analysis of promising approaches to improve its pharmacokinetic profile and anticancer efficacy.

Authors:  Muhammad Asim Farooq; Md Aquib; Daulat Haleem Khan; Zahid Hussain; Anam Ahsan; Mirza Muhammad Faran Ashraf Baig; Dickson Pius Wande; Muhammad Masood Ahmad; Hafiz Muhammad Ahsan; Jiang Jiajie; Bo Wang
Journal:  Daru       Date:  2019-11-22       Impact factor: 3.117

8.  Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells.

Authors:  P Liu; I S Kumar; S Brown; V Kannappan; P E Tawari; J Z Tang; W Jiang; A L Armesilla; J L Darling; W Wang
Journal:  Br J Cancer       Date:  2013-09-05       Impact factor: 7.640

9.  Comment on 'cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells'.

Authors:  B Cvek
Journal:  Br J Cancer       Date:  2013-01-22       Impact factor: 7.640

Review 10.  A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.

Authors:  Richard E Kast; John A Boockvar; Ansgar Brüning; Francesco Cappello; Wen-Wei Chang; Boris Cvek; Q Ping Dou; Alfonso Duenas-Gonzalez; Thomas Efferth; Daniele Focosi; Seyed H Ghaffari; Georg Karpel-Massler; Kirsi Ketola; Alireza Khoshnevisan; Daniel Keizman; Nicolas Magné; Christine Marosi; Kerrie McDonald; Miguel Muñoz; Ameya Paranjpe; Mohammad H Pourgholami; Iacopo Sardi; Avishay Sella; Kalkunte S Srivenugopal; Marco Tuccori; Weiguang Wang; Christian R Wirtz; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2013-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.